CytoMed Therapeutics Limited balance sheet GDTC

Annual Quarterly

As of Dec 31, 2025, CytoMed Therapeutics Limited had total assets of $6.2 million and total liabilities of $879,762. Total assets were down 15.7% from a year earlier. Stockholders' equity was $5.3 million. It held $1.6 million in cash and investments against $375,272 of total debt, net cash of $1.3 million. The current ratio, current assets divided by current liabilities, was 5.17.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Assets
Cash
2
-55.4%
4
-19.8%
5
+280.5%
1
Cash and investments
2
-55.4%
4
-19.8%
5
+280.5%
1
Receivables
1
+61.6%
1
-9.7%
1
+22.4%
1
Total current assets
3
-35.1%
4
-42.6%
8
+311.3%
2
Property and equipment, net
3
+20.6%
2
+52.1%
2
-15.2%
2
Total assets
6
-15.7%
7
-21.4%
9
+140.4%
4
Liabilities and equity
Accounts payable
0
+6.9%
0
-18.8%
0
+28.0%
0
Total current liabilities
1
+24.2%
0
-18.3%
1
-82.5%
3
Total liabilities
1
+17.4%
1
-12.1%
1
-75.4%
3
Stockholders' equity
5
-19.5%
7
-22.3%
9
+1848.5%
0
Debt
Debt due within a year
0
+15.3%
0
+7.2%
0
-89.7%
0
Long-term debt
0
-0.7%
0
-6.6%
0
-11.6%
0
Lease liabilities
0
+148.1%
0
+377.8%
0
-55.4%
0
Total debt
0
+10.7%
0
-0.2%
0
-44.4%
1
Net cash
1
-62.1%
3
-21.4%
4
+618.1%
1
Ratios
Current ratio
5.17x
9.89x
14.08x
0.60x
Debt to equity
0.07x
0.05x
0.04x
1.40x
Return on equity
-58.31%
-27.88%
-36.76%
-534.11%
Return on assets
-50.05%
-25.05%
-33.42%
-59.91%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GDTC (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Singapore
Headquarters
1 Commonwealth Lane, Singapore
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1873093
Former names
CytoMed Therapeutics Pte. Ltd. (until Nov 30, 2022)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.